Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ARC-101
- Development stage
- Preclinical
- Lead developer
- Araris Biotech
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
ARC-101 (also known as ARA-04-RKAA-PABC-MMAE) is a preclinical-stage, site-specific antibody-drug conjugate (ADC) developed by Araris Biotech (a subsidiary of Taiho Pharmaceutical) targeting Nectin-4. Built using Araris' proprietary AraLinQ conjugation platform, the drug consists of an anti-Nectin-4 monoclonal antibody (derived from enfortumab) enzymatically conjugated to the microtubule-disrupting cytotoxin monomethyl auristatin E (MMAE) via a hydrophilic RKAA peptide linker. This site-specific conjugation occurs at a privileged glutamine residue (Q295) within the antibody's Fc framework, yielding a highly homogeneous ADC with a drug-to-antibody ratio (DAR) of approximately 2. Preclinical studies demonstrate that ARC-101 possesses superior serum stability, an antibody-like pharmacokinetic profile, and enhanced anti-tumor efficacy with a significantly improved therapeutic index compared to enfortumab vedotin.
- Other names
- Araris anti-Nectin-4 ADCAraris Nectin-4 MMAE ADC
02
Targets
TUBB (Tubulin (alpha and beta subunits))PVRL4 (Nectin cell adhesion molecule 4)
Beyond the preview
Go deeper on ARC-101.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ARC-101.